The advent of BCR::ABL1 targeted tyrosine kinase inhibitors (TKIs) and has significantly enhanced clinical outcomes in patients with chronic-phase CML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.